Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lea Stitzlein

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|December 22, 2018
Emerging oral VEGF inhibitors for the treatment of renal cell carcinomaLea Stitzlein, Pss Rao, Richard Dudley
Currents in Pharmacy Teaching & Learning|March 23, 2023
Pharmacogenomics elective focused on advanced lab techniques, game-based learning, and business plan developmentJason W Guy, Lea Stitzlein, Richard Dudley, et al.
Microorganisms|August 6, 2020
Evaluating the Antiparasitic Activity of Novel BPZ Derivatives Against <i>Toxoplasma gondii</i>Olivia Hatton, Lea Stitzlein, Richard W Dudley, et al.
Pediatric Blood & Cancer|March 22, 2024
Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemiaSanila Sarkar, Emily Rav, Lea Stitzlein, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|December 22, 2018
Emerging oral VEGF inhibitors for the treatment of renal cell carcinomaLea Stitzlein, Pss Rao, Richard Dudley
Currents in Pharmacy Teaching & Learning|March 23, 2023
Pharmacogenomics elective focused on advanced lab techniques, game-based learning, and business plan developmentJason W Guy, Lea Stitzlein, Richard Dudley, et al.
Microorganisms|August 6, 2020
Evaluating the Antiparasitic Activity of Novel BPZ Derivatives Against <i>Toxoplasma gondii</i>Olivia Hatton, Lea Stitzlein, Richard W Dudley, et al.
Pediatric Blood & Cancer|March 22, 2024
Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemiaSanila Sarkar, Emily Rav, Lea Stitzlein, et al.
Pageof 1